Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

- PMLiVE

UK government launches ‘landmark’ AI breast cancer screening trial

Approximately 55,000 cases of the disease are diagnosed every year in the UK

- PMLiVE

World Cancer Day – CoppaFeel! and NHS NELCA urge young people to ‘Check In’

The co-designed campaign aims to challenge misconceptions surrounding breast cancer

- PMLiVE

Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer

An estimated 154,270 people will be diagnosed with cancer of the colon or rectum in the US this year

- PMLiVE

BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

- PMLiVE

Celebrating collective achievement – the power of collaboration

How partnerships in the pharma industry have become a cornerstone of progress

- PMLiVE

FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors

The conference will take place in Amsterdam from 8-9 October 2025

- PMLiVE

AstraZeneca’s Imfinzi recommended by CHMP to treat small cell lung cancer

Approximately 30% of small cell lung cancer patients have limited-stage disease

- PMLiVE

J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer

The formulation significantly reduces administration time compared to the approved intravenous version

- PMLiVE

MHRA approves CSL’s Andembry to treat angioedema attacks in HAE patients

The rare genetic condition occurs in approximately one in every 50,000 people in the UK

Why events should be part of your 2025 growth strategy

Over eighty per cent of businesses rank in-person events as their most impactful marketing channel. In fact, 48 per cent of teams say events are more important today than pre-pandemic. When done...

EatMoreFruit

- PMLiVE

Optimising business partnerships for success and sustainability

Building trust between all stakeholders to enhance business relationships and improve outcomes

- PMLiVE

Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links